Foundation Medicine (NASDAQ: FMI) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.
This is a summary of recent ratings and recommmendations for Foundation Medicine and Fulgent Genetics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility & Risk
Foundation Medicine has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.
Earnings & Valuation
This table compares Foundation Medicine and Fulgent Genetics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Foundation Medicine||$152.90 million||18.14||-$161.46 million||($4.50)||-16.71|
|Fulgent Genetics||$18.73 million||3.82||-$2.51 million||($0.11)||-36.36|
Fulgent Genetics has lower revenue, but higher earnings than Foundation Medicine. Fulgent Genetics is trading at a lower price-to-earnings ratio than Foundation Medicine, indicating that it is currently the more affordable of the two stocks.
This table compares Foundation Medicine and Fulgent Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
31.2% of Foundation Medicine shares are held by institutional investors. Comparatively, 7.9% of Fulgent Genetics shares are held by institutional investors. 2.7% of Foundation Medicine shares are held by company insiders. Comparatively, 58.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Fulgent Genetics beats Foundation Medicine on 8 of the 13 factors compared between the two stocks.
About Foundation Medicine
Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.
About Fulgent Genetics
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.